Cost-utility analysis of selective internal radiation therapy with Y-90 resin microspheres in hepatocellular carcinoma.
Noemi MuszbekEdit RemakRachel EvansVictoria K BrennanFabien ColaoneSuki ShergillDamian MullanPaul J RossPublished in: Future oncology (London, England) (2020)
Background: The study assessed the cost-utility of selective internal radiation therapy (SIRT) with Y-90 resin microspheres versus sorafenib in UK patients with unresectable hepatocellular carcinoma ineligible for transarterial chemoembolization. Materials & methods: A lifetime partitioned survival model was developed for patients with low tumor burden (≤25%) and good liver function (albumin-bilirubin grade 1). Efficacy, safety and quality of life data were from a European Phase III randomized controlled trial and published studies. Resource use was from registries and clinical surveys. Results: Discounted quality-adjusted life-years were 1.982 and 1.381, and discounted total costs were £29,143 and 30,927, for SIRT and sorafenib, respectively. Conclusion: SIRT has the potential to be a dominant (more efficacious/less costly) or cost-effective alternative to sorafenib in patients with unresectable hepatocellular carcinoma.
Keyphrases
- radiation therapy
- locally advanced
- phase iii
- randomized controlled trial
- liver metastases
- oxidative stress
- ischemia reperfusion injury
- open label
- clinical trial
- radiofrequency ablation
- cross sectional
- electronic health record
- molecularly imprinted
- double blind
- risk factors
- risk assessment
- human health
- systematic review
- placebo controlled
- quality improvement
- high resolution